title: Peptide and recombinant immunotherapy.
abstract: Because of the need to standardize allergen immunotherapy and the desire to reduce allergic adverse events during therapy, a transition to recombinant/synthetic hypoallergenic approaches is inevitable. Evidence supports the notion that effective therapy can be delivered using a limited panel of allergens or even epitopes, weakening the argument that all allergens must be present for optimal efficacy. Moreover, standardized products will allow direct comparisons between studies and, for the first time, immunotherapy studies will be truly blinded, allowing an accurate assessment of the actual treatment effect that can be achieved with this form of intervention.
authors.affiliation: Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, HSC 4H20, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada. larche@mcmaster.ca
authors.forename: Mark
authors.initials: M
authors.lastname: Larché
mesh_terms: D000485:Allergens / Q000276:immunology / Q000627:therapeutic use*; D000818:Animals; D003888:Desensitization, Immunologic; D000939:Epitopes / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D010455:Peptides / Q000276:immunology / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000485:Allergens; D000939:Epitopes; D010455:Peptides; D011994:Recombinant Proteins